Darunavir

1. Darunavir - CAS 206361-99-1 Catalog number: B0084- 062615 Darunavir is a second generation protease inhibitor that targets the HIV-1 protease. It demonstrates extremely potent activity against the infectivity and replication of various strains of HIV-1, including several that are resistant to first generation protease inhibitors (IC50s = 3-30 nM). Darunavir has been reported to inhibit both cell-free diffusion and cell-to-cell spread of HIV-1 with IC50 values of 2.5 and 2.8 nM, respectively. Please be kindly noted that our product can only be used for research to orgnizations or companies and we don't cooperate with personal buyers. Category Inhibitor Targets HIV SARS-CoV-2 Molecular Formula C27H37N3O7S Molecular Weight 547.67 Ordering Information Catalo Catalo g g Number Number Siz Siz e e Pric Pric e e Stoc Stoc k k Quantity Quantity In stoc k B0084- 062615 50 mg $289 0 Order Now Bulk Inquiry Chemical Information

2. Category Inhibitor Molecular Formula C27H37N3O7S Molecular Weight 547.67 Specification Properties Reference Reading Purity Purity ≥98% Related CAS Related CAS 635728-49-3 (Ethanolate) Appearance Appearance White to Pale Beige Solid Synonyms Synonyms TMC-114; TMC 114; TMC114; Prezista Clinical Trial Information NCT Number NCT Number Title Title Condition Condition Or Or Disease Disease Phase Phase Start Start Date Date Sponsor Sponsor Status Status NCT00081588 An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment- experienced Subjects. HIV Infection Phase 2 November 2003 Tibotec Pharmaceuticals, Ireland Completed NCT00115050 TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment HIV Infections Phase 3 June 2005 Tibotec Pharmaceuticals, Ireland Completed

3. Options NCT00245739 TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV- 1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens. HIV Infections Tibotec Pharmaceuticals, Ireland Approved for marketing NCT00260078 Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children HIV Infections Phase 2 February 2006 National Institute of Allergy and Infectious Diseases (NIAID) Completed NCT00355524 A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents HIV-1 Phase 2 June 2006 Tibotec Pharmaceuticals, Ireland Completed Preparing Stock Solutions 1 mg 1 mg 5 mg 5 mg 10 mg 10 mg ConcentrationVolumeMass ConcentrationVolumeMass 1 mM 1.8260 mL 9.1298 mL 18.2595 mL 5 mM 0.3652 mL 1.8260 mL 3.6519 mL 10 mM 0.1826 mL 0.9130 mL 1.8260 mL 50 mM 0.0365 mL 0.1826 mL 0.3652 mL

4. https://www.bocsci.com/darunavir-cas-206361-99-1-item-62615.html